Skip to Content

Vantas Valera Pharmaceuticals - Treatment for Prostate Cancer

Vantas is a long-acting implant designed for the continuous 12-month administration of histrelin, a synthetic nonapeptide agonist of luteinizing hormone-releasing hormone (LHRH). Vantas is indicated for the palliative treatment of advanced prostate cancer.

Posted: October 2004

Vantas (histrelin) FDA Approval History